Journey Medical Co. (NASDAQ:DERM – Get Free Report) CFO Joseph Benesch sold 4,055 shares of Journey Medical stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $5.40, for a total transaction of $21,897.00. Following the completion of the transaction, the chief financial officer now directly owns 56,655 shares in the company, valued at approximately $305,937. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Journey Medical Price Performance
NASDAQ DERM traded down $0.06 on Tuesday, hitting $5.41. 22,229 shares of the stock were exchanged, compared to its average volume of 143,702. Journey Medical Co. has a 52 week low of $1.60 and a 52 week high of $8.11. The stock has a market capitalization of $108.25 million, a P/E ratio of -17.81 and a beta of 0.92. The business has a fifty day simple moving average of $4.84. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.21 and a quick ratio of 0.94.
Journey Medical (NASDAQ:DERM – Get Free Report) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.27). Journey Medical had a negative net margin of 5.20% and a negative return on equity of 32.83%. The company had revenue of $13.03 million during the quarter, compared to analyst estimates of $14.91 million. Analysts predict that Journey Medical Co. will post -0.95 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Read Our Latest Report on Journey Medical
Hedge Funds Weigh In On Journey Medical
Several institutional investors and hedge funds have recently modified their holdings of DERM. Acadian Asset Management LLC grew its stake in Journey Medical by 687.5% during the first quarter. Acadian Asset Management LLC now owns 222,663 shares of the company’s stock worth $817,000 after buying an additional 194,389 shares in the last quarter. Rosalind Advisors Inc. bought a new position in shares of Journey Medical in the second quarter worth about $644,000. Heron Bay Capital Management bought a new position in shares of Journey Medical in the first quarter worth about $124,000. Finally, Nwam LLC bought a new position in Journey Medical in the 1st quarter valued at approximately $41,000. 7.25% of the stock is currently owned by institutional investors and hedge funds.
Journey Medical Company Profile
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Recommended Stories
- Five stocks we like better than Journey Medical
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- ScottsMiracle-Gro Stock Blooms After Investor Day Optimism
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Leading Beverage Company’s Stock Bubbles Higher: Rally Ahead
- Industrial Products Stocks Investing
- Can This Meme Stock Stage One Last Rally?
Receive News & Ratings for Journey Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Journey Medical and related companies with MarketBeat.com's FREE daily email newsletter.